Treatment of erythema migrans with doxycycline for 10 days versus 15 days

Clinical Infectious Diseases

Volumn 55, Issue 3, 2012, Pages 343-350

  Stupica, Daša ^a   Lusa, Lara ^b   Ružić Sabljić, Eva ^c   Cerar, Tjaša ^c   Strle, Franc ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b Institute for Biostatistics and Medical Informatics   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE;

ADULT; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTICLE; BORRELIA AFZELII; BORRELIA BURGDORFERI; BORRELIA GARINII; CONCENTRATION LOSS; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA CHRONICUM MIGRANS; EUROPE; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MEMORY DISORDER; MICROBIOLOGY; MYALGIA; NAUSEA; PARESTHESIA; PHOTOSENSITIVITY; PREVALENCE; PRIORITY JOURNAL; SOMNOLENCE; SPINAL PAIN; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTI-BACTERIAL AGENTS; DOXYCYCLINE; EUROPE; FEMALE; GLOSSITIS, BENIGN MIGRATORY; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 84863957106     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis402     Document Type: Article

References (36)

1. Steere AC, Hutchinson GJ, Rahn DW, et al. Treatment of the early manifestations of Lyme disease. Ann Intern Med 1983; 99:22-6.
2. Luger SW, Paparone P, Wormser GP, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother 1995; 39:661-7.
3. Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992; 117:273-80.
4. Dattwyler RJ, Volkman DJ, Conaty SM, Platkin SP, Luft BJ. Amoxicillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet 1990; 336:1404-6.
5. Massarotti EM, Luger SW, Rahn DW, et al. Treatment of early Lyme disease. Am J Med 1992; 92:396-403.
6. Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease. Ann Intern Med 2003; 138:697-704.
7. Dattwyler RJ, Luft BJ, Kunkel MJ, et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N Engl J Med 1997; 337:289-94.
8. Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. Ann Intern Med 1996; 124:785-91.
9. Strle F, Ruzic E, Cimperman J. Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin. J Antimicrobial Chemother 1992; 30:543-50.
10. Weber K, Wilske B, Preac-Mursic V, Thurmayr R. Azithromycin versus penicillin V for the treatment of early Lyme borreliosis. Infection 1993; 21:367-72.
11. Strle F, Preac-Mursic J, Cimperman J, Ruzic E, Maraspin V, Jereb M. Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings. Infection 1993; 21:83-8.
12. Breier F, Kunz G, Klade H, Stanek G, Aberer E. Erythema migrans: three weeks treatment for prevention of late Lyme borreliosis. Infection 1996; 24:69-72.
13. Barsic B, Maretic T, Majerus L, Strugar J. Comparison of azithromycin and doxycycline in the treatment of erythema migrans. Infection 2000; 28:153-6.
14. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089-134.
15. Cerar D, Cerar T, Ruži-Sablji E, Wormser GP, Strle F. Controlled prospective study on the development of subjective symptoms after treatment of early Lyme disease in Europe. Am J Med 2010; 123:79-86.
16. Wormser GP, O'Connell S. Treatment of infection caused by Borrelia burgdorferi sensu lato. Expert Rev Anti Infect Ther 2011; 9:245-60.
17. Stanek G, Gray J, Wormser GP, Strle F. Lyme borreliosis. Lancet 2012; 379:461-73.
18. Strle F, Nadelman RB, Cimperman J, et al. Comparison of cultureconfirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York State and by Borrelia afzelii in Slovenia. Ann Intern Med 1999; 130:32-6.
19. Strle F, Ruži-Sablji E, Logar M, et al. Comparison of erythema migrans caused by Borrelia burgdorferi and Borrelia garinii. Vector Borne Zoonotic Dis 2011; 11:1253-8.
20. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance: Lyme disease (Borrelia burgdorferi) 2008 Case Definition. Available at: http://www.cdc.gov/osels/ph- surveillance/nndss/print/lyme-disease-current.htm. Accessed 27 February 2012.
21. Wormser GP, Liveris D, Nowakowski J, et al. Association of specific subtypes of Borrelia burgdorferi with hematogenous dissemination in early Lyme disease. J Infect Dis 1999; 180:720-5.
22. Wilske B, Schierz G, Preac-Mursic V, Weber K, Pfister HW, Einhaupl K. Serological diagnosis of erythema migrans disease and related disorders. Infection 1984; 5:331-7.
23. Preac-Mursic V, Wilske B, Schierz G. European Borrelia burgdorferi isolated from humans and ticks. Culture conditions and antibiotic susceptibility. Zentral Bakteriol Mikrobiol Hyg 1986; 263:112-8.
24. Cerar T, Ruži-Sablji E, Glinšek U, Zore A, Strle F. Comparison of PCR methods and culture for the detection of Borrelia spp. in patients with erythema migrans. Clin Microbiol Infect 2008; 14:653-8.
25. R Development Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2009. Available at: http://www.R-project.org. Accessed 15 July 2011.
26. Rubinstein E. Short antibiotic treatment courses or how short is short? Int J Antimicrob Agents 2007; 30(Suppl 1):76-9.
27. Cairns V, Godwin J. Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms. Int J Epidemiol 2005; 34:1340-5.
28. Shapiro ED, Dattwyler R, Nadelman RB, Wormser GP. Response to meta-analysis of Lyme borreliosis symptoms. Int J Epidemiol 2005; 34:1437-9.
29. Feder HM, Johnson BJB, O'Connell S; and the Ad Hoc International Lyme Disease Group. A critical appraisal of "chronic Lyme disease." N Engl J Med 2007; 357:1422-30.
30. The Swedish medicines agency (Lakemedelsvärket).Treatment of borrelia infection. Available at: http://www.lakemedelsverket.se/malgrupp/ Allmanhet/Att-anvanda-lakemedel/Sjukdom-och-behandling/ Behandlingsrekommendationer-listan/Borrelia. Accessed 27 February 2012.
31. Yong CKK, Prendiville J, Peacock DL, Wong LTK, Davidson AGF. An unusual presentation of doxycycline-induced photosensitivity. Pediatrics 2000; 106:E13. Available at: http://pediatrics.aappublications.org/content/106/1/e13.long. Accessed 15 July 2011.
32. Bjellerup M, Ljunggren B. Differences in phototoxic potency should be considered when tetracyclines are prescribed during summertime: a study on doxycycline and lymecycline in human volunteers, using an objective method for recording erythema. Br J Dermatol 1994; 130: 356-60.
33. Layton AM, Cunliffe WJ. Phototoxic eruptions due to doxycycline-a dose related phenomenon. Clin Exp Dermatol 1993; 18:425-7.
34. Lantos PM. Chronic Lyme disease: the controversies and the science. Expert Rev Anti Infect Ther 2011; 9:787-97.
35. Stupica D, Lusa L, Cerar T, Ruži-Sablji E, Strle F. Comparison of post-Lyme borreliosis symptoms in erythema migrans patients with positive and negative Borrelia burgdorferi sensu lato skin culture. Vector Borne Zoonotic Dis 2011; 11:883-9.
36. Nowakowski J, Nadelman RB, Sell R, et al. Long-term follow-up of patients with culture-confirmed Lyme disease. Am J Med 2003; 115: 91-6.